Parathyroid hyperplasia, adenomas, and carcinomas: Differential expression of p27(Kip1) protein

American Journal of Surgical Pathology

Volumn 23, Issue 3, 1999, Pages 288-295

  Erickson, Lori A ^a   Jin, Long ^a   Wollan, Peter ^a   Thompson, Geoffrey B ^a   Van Heerden, Jon A ^a   Lloyd, Ricardo V ^a,b  

^a MAYO CLINIC   (United States)

^b Laboratory Medicine and Pathology   (United States)

Author keywords

Cell cycle; Ki67; MIB1; p27; Parathyroid

Indexed keywords

COMPLEMENTARY RNA; KI 67 ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY KI 67; PROTEIN P27;

ADULT; ARTICLE; CELL CYCLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID HYPERPLASIA; PROTEIN EXPRESSION;

ADENOMA; ADULT; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MUSCLE PROTEINS; PARATHYROID GLANDS; PARATHYROID NEOPLASMS; RNA, MESSENGER;

EID: 0033011830     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199903000-00007     Document Type: Article

References (39)

1. Abbona GC, Papotti M, Gasparri G, Bussolati G. Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol 1995;26:135-8.
2. Arnold A, Staunton CE, Kim HG, Gaz RD, Kronenberg HM. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med 1988;318:658-62.
3. Catzavelos C, Bhattachara N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip protein: prognostic implication in primary breast cancer. Nature Med 1997;3:227-30.
4. Cheville JC, Lloyd RV, Sebo TJ, et al. Expression of p27kip1 in prostate adenocarcinomas. Mod Pathol 1998;11:324-8.
5. DeLellis RA. Tumors of the parathyroid gland. In: Atlas of tumor pathology, Third Series: Fascicle 6. Editor: J. Rosai. Washington, DC: Armed Forces Institute of Pathology, 1992.
6. Erickson LA, Jin L, Wollan PC, Thompson GB, Lloyd RV. Expression of p27Kip1 in benign and malignant thyroid tissues. Mod Pathol 1998;11:169-74.
7. Esposito V, Baldi A, DeLuca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;15:57:3381-5.
8. Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficienf mice. Cell 1996;85:733-44.
9. Fredersdorf S, Burns J, Milne A, et al. High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94: 6380-65.
10. Friedman E, Bale AE, Marx SJ, et al. Genetic abnormalities in sporadic parathyroid adenomas. J Clin Endocrinol Metab 1990;71: 293-7.
11. Friedman E, Sakaguchi K, Bale AE, et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type I. N Engl J Med 1989;321:213-8.
12. Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133:1710-5.
13. Hengst L, Reed S. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996;271:1861-4.
14. Hsi ED, Zukerberg LR, Yang W, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 1996;81:1736-9.
15. Jin L, Quan X, Kulig E, et al. Transforming growth factor-B. transforming growth factor-B receptor II, and p27 Kip1 expression in non-tumorous and neoplastic human pituitaries. Am J Pathol 1997;151:509-19.
16. Karak AK, Sarkar C, Chumber S, Tandon N. MIB-1 proliferative index in parathyroid adenoma and hyperplasia. Indian J Med Res 1997;105:235-8.
17. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721-32.
18. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-B. Science 1993;260:536-9.
19. Lloyd RV, Carney JA, Ferreiro JA, et al. Immunohistochemical analysis of the cell cycle-associated protein in parathyroid carcinomas and adenomas. Endocrine Pathol 1995;6:279-87.
20. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 1997;150:401-7.
21. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997;3:231-4.
22. Loda M, Lipman J, Cukor B, Bur M, Kwan P, DeLellis RA. Nodular foci in parathyroid adenomas and hyperplasias: an immunohistochemical analysis of proliferative activity. Hum Pathol 1994;25:1050-6.
23. Pagano M, Tam SW, Theodoras AM, et al.Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
24. Pietenpol JA, Bohlander SK, Sato Y, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995;55:1206-10.
25. Polyak K, Kato JV, Soloman MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
26. Ponce-Castaneda MV, Lee MH, Latres E, et al. p27Kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55:1211-3.
27. Porter P, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1996;3:222-4.
28. Qian X, Jin L, Grande JP, Lloyd RV. Transforming growth factor-B and p27 expression in pituitary cells. Endocrinology 1996; 137:3051-60.
29. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland S. G1 control in mammalian cells. J Cell Sci 1994;18(suppl):69-73.
30. Rivard N, L'Allemain G, Bartek J, Pouyssegur J. Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (GO state) in fibroblasts. J Biol Chem 1996;271:18337-41.
31. Roth SI. Parathyroid glands. In: Damjanov I, Linder J (eds). Anderson's pathology. 10th ed. St. Louis: C.V. Mosby, 1996:1980-2007.
32. Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973;31:600-5.
33. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclindependent kinases. Genes Dev 1995;9:1149-63.
34. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI. A novel inhibitor of cyclin/Cdk activity detected in TGF-β arrested epithelial cells. Molec Cell Biol 1994;14:3683-94.
35. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a.b) invasive breast carcinomas. Cancer Res 1997;57:1259-63.
36. Weiss LM. Comparative histologic study of 43 metastasizing and non-metastasizing adrenocortical tumors. Am J Surg Pathol 1984; 8:163-9.
37. Vargas MP, Vargas HI, Kleiner DE, Merino MJ. The role of prognostic markers (MiB-1, RB. and Bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 1997;10:12-7.
38. Vanables WN, Ripley BD. Modern applied statistics with S-Plus. Berlin:Springer-Verlag, 1994.
39. Yasui W, Kudo Y, Semba S, Yokozaki H, Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 1997;88:625-9.